Cite
APA Citation
Chesney, J., Imbert-Fernandez, Y., Telang, S., Baum, M., Ranjan, S., Fraig, M., & Batty, N. (2018). potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma research, 28(3), . http://access.bl.uk/ark:/81055/vdc_100084037012.0x00001d